Rujukan Ranbaxy Laboratories

  1. ↑ "Annual Report 2012" (PDF). Ranbaxy Laboratories Limited. Diarkib daripada yang asal (PDF) pada 5 November 2013.
  2. ↑ Matsuyama, Kanoko; Chatterjee, Saikat (June 11, 2008). "Daiichi to Take Control of Ranbaxy for $4.6 Billion (Update3) - Bloomberg". Bloomberg.com. Bloomberg LP. Diarkib daripada yang asal pada 2014-12-02. Dicapai pada 2018-08-11.
  3. 1 2 "Sun Pharma to acquire Ranbaxy for $4 billion in all-share deal". IANS. news.biharprabha.com. Dicapai pada 7 April 2014.
  4. ↑ "Ranbaxy: Ranbaxy Continues to Add Value and Utility to US Product Portfolio". pharmacytimes.com. Pharmacy Times. Dicapai pada 11 August 2018. Ranbaxy [..] entered the U.S. generic pharmaceutical market in 1995 introducing its first product under the Ranbaxy Pharmaceuticals Inc. label in January 1998
  5. ↑ Patent ruling hits Ranbaxy shares – 19 December 2005. BBC News (19 December 2005).
  6. ↑ "Bloomberg - Are you a robot?". www.bloomberg.com.
  7. ↑ "Ranbaxy gets approval to launch generic Lipitor in US – The Times of India". The Times of India.
  8. ↑ Staff (June 12, 2008). "The Ranbaxy-Daiichi Deal: Good Medicine, or a Harbinger of Future Ills? - Knowledge@Wharton". Knowledge@Wharton. Wharton School of Business. Dicapai pada 2018-08-11.
  9. ↑ "Ranbaxy joined "Online Pharma Exhibition"". Diarkib daripada yang asal pada 31 January 2013.
  10. ↑ TimesOnlineUK – Business – Takeover of Ranbaxy
  11. ↑ Matsuyama, Kanoko. (11 June 2008) Daiichi to Take Control of Ranbaxy for $4.6 Billion – 11 June 2008. Bloomberg.
  12. ↑ Chatterjee, Surojit (12 June 2008). "Japanese drugmaker Daiichi Sankyo gobbles Ranbaxy Laboratories for $4.6 billion". International Business Times. New York. Diarkib daripada yang asal pada 16 November 2009.
  13. ↑ "Ranbaxy Laboratories Limited > Contact Us > Worldwide Operations > India". Ranbaxy.com. Diarkib daripada yang asal pada 4 April 2012.
  14. ↑ ET Bureau (11 September 2009). "Yugal Sikri to be New India CEO of Ranbaxy – Economic Times". The Economic Times.
  15. ↑ "India's Most Trusted Brands 2014". Trust Research Advisory. Diarkib daripada yang asal pada 2 Mei 2015.
  16. ↑ "India's Sun Pharma to Buy Ranbaxy in $4 Billion Deal". Dicapai pada 2014-04-06.
  17. 1 2 Eban, Katherine (2013-05-15). "Dirty Medicine". Fortune. Dicapai pada 2018-02-06. — an in-depth investigation of Ranbaxy Laboratories
  18. ↑ "FDA Issues Warning Letters to Ranbaxy Laboratories Ltd., and an Import Alert for Drugs from Two Ranbaxy Plants in India. Actions affect over 30 different generic drugs; cites serious manufacturing deficiencies". Press Announcement. Food and Drug Administration. 16 September 2008. Dicapai pada 1 June 2013.
  19. ↑ "FDA Takes New Regulatory Action Against Ranbaxy's Paonta Sahib Plant in India. Agency halts review of drug applications from plant due to evidence of falsified data; invokes Application Integrity Policy". Press Announcement. Food and Drug Administration. 25 February 2009. Dicapai pada 1 June 2013. The FDA's investigations revealed a pattern of questionable data raising significant questions regarding the reliability of certain applications, and this warrants applying the Application Integrity Policy, said Deborah Autor, director of CDER's Office of Compliance.
  20. ↑ "KNMP waarschuwt voor verontreinigde tabletten —" (dalam bahasa Belanda). Gezondheidskrant.nl.
  21. ↑ Following Earlier Recall, Ranbaxy Halts Manufacturing Atorvastatin. Forbes.
  22. ↑ Loftus, Peter (29 November 2012). "Ranbaxy Halts Production of Generic Lipitor". The Wall Street Journal. Diarkib daripada yang asal pada 26 February 2014. Dicapai pada 10 March 2014.(subscription required)
  23. ↑ "Ranbaxy recalls over 64,000 bottles of generic Lipitor in US". Business Standard. India. Press Trust of India. 8 March 2014. Diarkib daripada yang asal pada 10 March 2014. Dicapai pada 10 March 2014.
  24. ↑ "Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA". The United States Department of Justice. Office of Public Affairs. 13 May 2013. Dicapai pada 1 January 2018.
  25. ↑ "India drug firm pays record US fine". BBC News (dalam bahasa Inggeris). 2013-05-14. Dicapai pada 2018-01-03.
  26. ↑ Bureau, Our. "FDA finds quality, process lapses at Ranbaxy plant". @businessline.
  27. ↑ Ranbaxy import ban: US FDA found suspected hair, oil in tablets Diarkibkan 23 September 2013 di Wayback Machine
  28. ↑ "FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy's Mohali, India, plant and issues import alert". Press Announcement. Food and Drug Administration. 2013-09-16. Dicapai pada 2013-10-08. The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.’s facility in Mohali, India. The firm will remain on the import alert until the company complies with U.S. drug manufacturing requirements, known as current good manufacturing practices (CGMP).
  29. ↑ "FDA prohibits Ranbaxy's Toansa, India facility from producing and distributing drugs for the U.S. market". Food and Drug Administration. Diarkib daripada yang asal pada 12 Januari 2017. Dicapai pada 1 Januari 2018.Selenggaraan CS1: BOT: status original-url tidak dikenali (link)
  30. ↑ "India's Ranbaxy hit by FDA product ban at 4th Indian plant". Reuters. 2014-01-24. Dicapai pada 2018-01-03.
  31. ↑ Eban, Katherine (May 14, 2019). Bottle of Lies. ISBN 9780062338785.
  32. ↑ Jonathan Lambert. "'Bottle Of Lies' Exposes The Dark Side Of The Generic-Drug Boom".

Rujukan

WikiPedia: Ranbaxy Laboratories http://news.biharprabha.com/2014/04/sun-pharma-to-... http://www.business-standard.com/article/pti-stori... http://fortune.com/2013/05/15/dirty-medicine/ http://articles.economictimes.indiatimes.com/2009-... http://timesofindia.indiatimes.com/business/india-... http://www.niticentral.com/2013/09/18/ranbaxy-impo... http://www.pharmaexhibition.com/Exhibit/Ranbaxy-La... http://www.ranbaxy.com/common/ContactRegion.aspx?i... http://www.ranbaxy.com/wp-content/uploads/2013/03/... http://knowledge.wharton.upenn.edu/article/the-ran...